KRAS Mutations As an Independent Prognostic Factor in Patients With Advanced Colorectal Cancer Treated With Cetuximab
作者： Fréderic Bibeau , Marie-Danièle Diebold , Philippe Rougier , Michel Ducreux , Gorana Tomasic
关键词:
摘要: Purpose Cetuximab is efficient in advanced colorectal cancer (CRC). We previously showed that KRAS mutations were associated with resistance to cetuximab 30 CRC patients. The aim of this study was validate, an independent larger series 89 patients, the prognostic value on response and survival. Patients Methods Eighty-nine metastatic patients treated after treatment failure irinotecan-based chemotherapy analyzed for mutation by allelic discrimination tumor DNA. association between response, skin toxicity, progression-free survival (PFS) overall (OS) analyzed. Results A present 27% (0% v 40% responders among 24 mutated 65 nonmutated respectively; P < .001) a poorer (median PFS: 10.1 31.4 weeks without mutation; = .0001; median OS: 14.3 mon...
archives-ouvertes.fr
nlm.it 参考文章(23)
Mohamed Hebbar, Agne`s Wacrenier, Christophe Desauw, Olivier Romano, Ste??phane Cattan, Jean-Pierre Triboulet, Francois-Rene?? Pruvot, Lack of usefulness of epidermal growth factor receptor expression determination for cetuximab therapy in patients with colorectal cancer. Anti-Cancer Drugs. ,vol. 17, pp. 855- 857 ,(2006) , 10.1097/01.CAD.0000217425.44584.9F
Frédérique Penault-Llorca, Anne Cayre, Laurent Arnould, Frédéric Bibeau, Marie-Pierre Bralet, Philippe Rochaix, Jacqueline Savary, Jean-Christophe Sabourin, Is there an immunohistochemical technique definitively valid in epidermal growth factor receptor assessment Oncology Reports. ,vol. 16, pp. 1173- 1179 ,(2006) , 10.3892/OR.16.6.1173
Deborah Schrag, The price tag on progress--chemotherapy for colorectal cancer. The New England Journal of Medicine. ,vol. 351, pp. 317- 319 ,(2004) , 10.1056/NEJMP048143
Wu Zhang, Michael Gordon, Oliver A. Press, Katrin Rhodes, Daniel Vallböhmer, Dong Yun Yang, David Park, William Fazzone, Anne Schultheis, Andy E. Sherrod, Syma Iqbal, Susan Groshen, Heinz-Josef Lenz, Cyclin D1 and epidermal growth factor polymorphisms associated with survival in patients with advanced colorectal cancer treated with Cetuximab Pharmacogenetics and Genomics. ,vol. 16, pp. 475- 483 ,(2006) , 10.1097/01.FPC.0000220562.67595.A5
M. Francoual, M.-C. Etienne-Grimaldi, J.-L. Formento, D. Benchimol, A. Bourgeon, M. Chazal, C. Letoublon, T. André, N. Gilly, J.-R. Delpero, P. Lasser, J.-P. Spano, G. Milano, EGFR in colorectal cancer: more than a simple receptor Annals of Oncology. ,vol. 17, pp. 962- 967 ,(2006) , 10.1093/ANNONC/MDL037
Daniel Vallböhmer, Wu Zhang, Michael Gordon, Dong Yun Yang, Jim Yun, Oliver A. Press, Katrin E. Rhodes, Andy E. Sherrod, Syma Iqbal, Kathleen D. Danenberg, Susan Groshen, Heinz-Josef Lenz, Molecular Determinants of Cetuximab Efficacy Journal of Clinical Oncology. ,vol. 23, pp. 3536- 3544 ,(2005) , 10.1200/JCO.2005.09.100
A. de Gramont, A. Figer, M. Seymour, M. Homerin, A. Hmissi, J. Cassidy, C. Boni, H. Cortes-Funes, A. Cervantes, G. Freyer, D. Papamichael, N. Le Bail, C. Louvet, D. Hendler, F. de Braud, C. Wilson, F. Morvan, A. Bonetti, Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer Journal of Clinical Oncology. ,vol. 18, pp. 2938- 2947 ,(2000) , 10.1200/JCO.2000.18.16.2938
Mauro Moroni, Silvio Veronese, Silvia Benvenuti, Giovanna Marrapese, Andrea Sartore-Bianchi, Federica Di Nicolantonio, Marcello Gambacorta, Salvatore Siena, Alberto Bardelli, Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study Lancet Oncology. ,vol. 6, pp. 279- 286 ,(2005) , 10.1016/S1470-2045(05)70102-9
Richard M. Goldberg, Daniel J. Sargent, Roscoe F. Morton, Charles S. Fuchs, Ramesh K. Ramanathan, Stephen K. Williamson, Brian P. Findlay, Henry C. Pitot, Steven R. Alberts, A Randomized Controlled Trial of Fluorouracil Plus Leucovorin, Irinotecan, and Oxaliplatin Combinations in Patients With Previously Untreated Metastatic Colorectal Cancer Journal of Clinical Oncology. ,vol. 22, pp. 23- 30 ,(2004) , 10.1200/JCO.2004.09.046
JY Douillard, D Cunningham, AD Roth, M Navarro, RD James, P Karasek, P Jandik, T Iveson, J Carmichael, M Alakl, G Gruia, L Awad, P Rougier, Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial The Lancet. ,vol. 355, pp. 1041- 1047 ,(2000) , 10.1016/S0140-6736(00)02034-1